DRMAW

distress 8/10 · high distress / dilution risk

$0.020%today-3% from 52w high

dermatarx.com9 employeesFounded 2014San Diego, CA

Lead: moderate-to-severe acne

Revenue

pre-revenue

Liquidity

$7M

Runway

0.8 yrs

Shares 1y

+490%

Price & events

-2.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.0%

—

-2.7%

All

Overview

Market Cap: $73.61K
Volume: 0
52 Week Range: $0.02 – $0.02
Total Shares: 4.02M
Float Shares: 3.17M
Beta: 0.67

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 4

first half of 2028Guided 55%regulatory submissionFiled (NDA/BLA)XYNGARI · NDA filing for XYNGARISEC 8-K
first half of 2027Guided 55%readoutPhase 3XYNGARI · Topline results from STAR-2 trialSEC 8-K
second half of 2025trial initiationsecondaryPhase 3XYNGARI · Initiation of second Phase 3 trial STAR-2SEC 8-K
2025-08-22rtorRegained compliance with Nasdaq minimum bid price requirementSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 4,022,143 · 4 offerings/1y · 1 PIPEs

2026-05-29424B3offering
2026-05-29EFFECTshelf_effective
2026-05-22S-3/Ashelf_registration
2026-01-29EFFECTshelf_effective
2026-01-29424B3offering
2026-01-27424B5offering
2026-01-22S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — moderate-to-severe acne

none identified